دورية
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
| العنوان: | First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial |
|---|---|
| المؤلفون: | Morgan, Gareth J, Davies, Faith E, Gregory, Walter M, Cocks, Kim, Bell, Sue E, Szubert, Alex J, Navarro-Coy, Nuria, Drayson, Mark T, Owen, Roger G, Feyler, Sylvia, Ashcroft, A John, Ross, Fiona, Byrne, Jennifer, Roddie, Huw, Rudin, Claudius, Cook, Gordon, Jackson, Graham H, Child, J Anthony |
| المصدر: | The Lancet; December 2010, Vol. 376 Issue: 9757 p1989-1999, 11p |
| مستخلص: | Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies. We aimed to establish whether bisphosphonates can affect clinical outcomes in patients with multiple myeloma. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 01406736 1474547X |
|---|---|
| DOI: | 10.1016/S0140-6736(10)62051-X |